💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers an integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, slow-growing business, fully valued.
Laurus Labs is scored on the pharma / healthcare framework. It keeps a healthy 13.0% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.82× reported profit. Free cash flow is worth about 0.4% of its market value.
Over the last 3 years revenue compounded at 4%/yr and profit at 4%/yr. Book value has grown 10%/yr. Return on equity is an elite 22.1%. In the latest quarter profit grew 21% versus the prior quarter.
At 142× earnings, the stock sits at the 61st percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~31%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 94.69 | — | — |
| P/B | 20.82 | 4.1 | worse |
| EV/EBITDA | 53.44 | 19.33 | worse |
| ROE | 22.11 | — | — |
| ROCE | 20.91 | 14.41 | better |
| ROA | 11.58 | — | — |
| Quick Ratio | 0.68 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
4% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
The latest year saw a +151% swing — check if it's a one-off or structural.
Operating margins have been stable around 17% — no major structural shift.
ROE at 16% — a respectable return on shareholder capital.
4% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.8× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 9% sequentially — momentum is building. Run-rate stepping up — recent quarters average 18% above earlier ones.
Profit jumped 21% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (14% → 20%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold just 27.5% — widely held; sentiment-driven. FII stake up 4.3pp over 4 quarters — growing foreign interest.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.